Rapid Micro Biosystems financials
$1.08−1.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M |
| Gross profit | $1.0M | -$109.0K | -$5.5M | -$8.5M | -$7.7M |
| Gross margin | 3.1% | −0.4% | −24.4% | −49.8% | −33.3% |
| Operating income | -$47.4M | -$49.9M | -$56.6M | -$63.2M | -$47.2M |
| Net income | -$47.1M | -$46.9M | -$52.5M | -$60.8M | -$78.0M |
| Net margin | −140.3% | −167.2% | −233.0% | −354.9% | −335.9% |
| Diluted EPS | $-1.05 | $-1.08 | $-1.22 | $-1.43 | $-3.94 |
| EBITDA | -$44.1M | -$46.6M | -$53.5M | -$60.4M | -$45.7M |
| Operating cash flow | -$31.1M | -$44.2M | -$45.1M | -$58.5M | -$55.0M |
| Free cash flow | -$31.9M | -$45.5M | -$46.9M | -$65.3M | -$58.2M |
| Diluted shares | 44.7M | 43.6M | 43.0M | 42.5M | 19.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $20.0M | $16.9M | $24.3M | $27.1M | $178.4M |
| Short-term investments | $18.3M | $33.8M | $67.8M | $81.6M | $15.1M |
| Total debt | $18.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $74.9M | $98.2M | $143.5M | $190.7M | $241.2M |
| Total liabilities | $41.6M | $22.8M | $25.5M | $26.5M | $20.2M |
| Shareholders' equity | $33.2M | $75.4M | $118.0M | $164.2M | $221.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology